Study Effect of VIA-2291 on Vascular Inflammation

Inclusion Criteria: * Female patients are to be of non-childbearing potential * Patient has suffered an ST elevation myocardial infarction (MI), non-ST elevation MI, or unstable angina 21 days (±3 days) prior to study randomization * Patient has documented coronary artery disease Exclusion Criteria: * Renal insufficiency defined as creatinine \>1.5 x upper limit of normal (ULN) * Cirrhosis, recent hepatitis, ALT \>1.5 x ULN or ALT \> 1 x ULN and at least one other liver function test * Uncontrolled diabetes mellitus within 1 month prior to study screening * Congestive heart failure (CHF) defined by the New York Heart Association as functional Class III or IV * Previous coronary artery bypass graft (CABG) surgery * Planned additional cardiac intervention * Recurrence of ST elevation MI, non-ST elevation MI, or unstable angina less than 18 days prior to randomization * Current atrial fibrillation, atrial flutter, or frequent premature ventricular contractions * Acetaminophen use in any form in the 7 days before enrollment